CompletedPhase 1

Clinical Trial to Evaluate the Safety, Pharmacokinetic Characteristics of DW5124 and DW5124-R, and the Effect of Food on DW5124 in Healthy Adult Volunteers

South Korea55 participantsStarted 2025-05-08

Plain-language summary

This study aimed to evaluate the safety and pharmacokinetic characteristics of DW5124 and DW5124-R, and the effect of food on DW5124, in healthy adult volunteers.

Who can participate

Age range19 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Healthy Volunteers who are ≥19 years and \>65 years old * Body weight ≥50.0 kg and BMI between 18.0 and 30.0 kg/m2 Exclusion Criteria: * Clinically significant Medical History * In the case of women, pregnant(Urine-HCG positive) or lactating women

What they're measuring

Peak Plasma Concentration (Cmax)

Timeframe: up to 72 hour

Area under the plasma concentration versus time curve (AUC)

Timeframe: up to 72 hour

Trial details

NCT IDNCT07319559

SponsorDaewon Pharmaceutical Co., Ltd.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2025-05-11

View on ClinicalTrials.gov More Mixed Dyslipidemia trials